ALLR (Allarity Therapeutics) רווח נקי למניה (EPS TTM)

Allarity Therapeutics (ALLR) is currently revising its drug portfolio, leveraging AI technologies and the search for new partners. The company's net profit per share over 12 months on this chart demonstrates yield dynamics, where -0.98 describes the current status of the metric. Strong pricing power is ensured by the precise selection of RNA therapy, however, capital shortages and complexities in test implementation create serious risks for the business's survival.
פילוחי מדדים ואנליטיקה של חברת allarity.com (ALLR)

Allarity Therapeutics (ALLR) is implementing robotic biochemical screening to accelerate preclinical research. This indicator measures net income allocated per share over the last twelve months. It allows for an assessment of business capitalization efficiency and identifies the impact of one-off factors on profitability. It is critical for investors to distinguish between real growth and temporary anomalies. The company's rolling annual earnings per share clearly demonstrates the speed of the business's adaptation to market conditions.